In a two-year trial involving 394 patients with untreated hypertension, Zilebesiran, an injection-based medication, was tested at different doses. The results demonstrated significant reductions in mean blood pressure, with the 150 mg dose leading to a 14.1 mmHg reduction, the 300 mg dose to a 16.7 mmHg reduction, and the 600 mg dose to a 15.7 mmHg reduction. Zilebesiran, which inhibits the production of the AGT gene, showed promise in achieving clinically significant reductions in systolic blood pressure. If successful in further studies, Zilebesiran could revolutionise hypertension treatment, offering a more convenient and potentially more effective solution for patients.
What are your thoughts on the potential impact of Zilebesiran as a new treatment for hypertension?